After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Magenta Therapeutics Inc. (MGTA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0043, or 0.89%, to $0.49. The Magenta Therapeutics Inc. has recorded 7,023 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial.
MGTA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $0.49 and fluctuated between $0.5050 as its day high and $0.4709 as its day low. The current market capitalization of Magenta Therapeutics Inc. is $27.77M. A total of 0.68 million shares were traded on the day, compared to an average of 1.54M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, MGTA has seen 5 BUY and 0 SELL insider trades, representing the acquisition of 15,000 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 0 SELLs from insiders. Insiders purchased 27,000 shares during that period but sold 0.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for MGTA in the last 3 months, the mean price target is $2.67 with high estimates of $3.00 and low estimates of $2.00. In terms of 52-week highs and lows, MGTA has a high of $4.50 and a low of $0.32.
As of this writing, MGTA has an earnings estimate of -$0.3 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.27 per share and a lower estimate of -$0.32. The company reported an EPS of -$0.39 in the last quarter, which was -25.80% lower than expectations of -$0.31.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MGTA is Buy with a score of 4.50. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.